Segal G H, Masih A S, Fox A C, Jorgensen T, Scott M, Braylan R C
Department of Pathology, University of Florida College of Medicine, Gainesville.
Blood. 1995 Mar 15;85(6):1570-9.
Mantle cell lymphomas (MCLs) are typically CD5-expressing B-cell non-Hodgkin's lymphomas (NHLs) that frequently harbor the chromosomal translocation t(11;14) or bcl-1 gene rearrangements. Insufficient data are available on the biologic features and clinical behavior of rigorously characterized MCL. As these NHLs have been reported to exhibit various histologic and cytologic expressions, and in order to avoid using somewhat arbitrary and subjective morphologic definitions, we chose to study cases of MCL selected on more objective grounds. Specifically, 15 samples (from 14 patients) of CD5-expressing B-cell NHLs with detectable bcl-1 gene rearrangement were included. Overall, these patients had relatively uniform clinical manifestations. Most were older men (mean age, 67 years) who presented with lymphadenopathy, high-stage disease, and bone marrow involvement. All but two patients relapsed, demonstrated residual tumor, or had disease progression after an initial response to various therapies. Nine patients have died; these patients had a median survival of only 19 months. All cases could be classified within the broad morphologic spectrum previously described for MCL, and no predominant histologic subtype was observed. However, cases could be segregated into two major groups according to tissue architecture: one with a purely diffuse pattern and the other with at least a focal nodular component. Patients with purely diffuse tumors had a lower survival rate (0%) than those with tumors having a nodular component (62% survival rate). In contrast to the morphologic variability, these NHL exhibited a rather homogeneous immunophenotypic pattern. All cases demonstrated intense CD20 expression, with typically intense IgM and light chain expression, and relatively weak IgD expression. In no case was CD10 detected on the neoplastic cells. DNA content analysis showed aneuploidy only in three instances, and two groups of cases could be arbitrarily defined on the basis of their S-phase fraction. A relationship between a purely diffuse growth pattern and a high S-phase fraction (greater than 5%) was observed. As expected from this association, patients with tumors having high S-phase fractions fared worse (14% survival rate) than those patients with tumors showing lower S-phase fractions (57% survival rate). Thirteen NHLs from 12 patients had amplifiable bcl-1 gene rearrangements at the major translocation cluster (MTC). The bcl-1 breakpoints aggregated within a 63-bp region of the MTC, and the amplified tumor DNA from each patient had unique N-nucleotide junctional sequences and Ig joining region breakpoint sites.(ABSTRACT TRUNCATED AT 400 WORDS)
套细胞淋巴瘤(MCL)通常是表达CD5的B细胞非霍奇金淋巴瘤(NHL),常伴有染色体易位t(11;14)或bcl-1基因重排。关于严格定义的MCL的生物学特征和临床行为的数据不足。由于据报道这些NHL表现出各种组织学和细胞学表达,并且为了避免使用有些随意和主观的形态学定义,我们选择基于更客观的标准来研究MCL病例。具体而言,纳入了15份(来自14名患者)表达CD5的B细胞NHL样本,这些样本可检测到bcl-1基因重排。总体而言,这些患者的临床表现相对一致。大多数是老年男性(平均年龄67岁),表现为淋巴结病、晚期疾病和骨髓受累。除两名患者外,所有患者均复发、有残留肿瘤或在对各种治疗的初始反应后疾病进展。9名患者死亡;这些患者的中位生存期仅为19个月。所有病例均可归类于先前描述的MCL的广泛形态学范围内,未观察到主要的组织学亚型。然而,根据组织结构,病例可分为两大组:一组为纯弥漫性模式,另一组至少有局灶性结节成分。纯弥漫性肿瘤患者的生存率(0%)低于有结节成分肿瘤的患者(生存率62%)。与形态学变异性相反,这些NHL表现出相当一致的免疫表型模式。所有病例均显示CD20强烈表达,通常IgM和轻链表达强烈,而IgD表达相对较弱。肿瘤细胞上未检测到CD10。DNA含量分析仅在3例中显示非整倍体,两组病例可根据其S期分数任意定义。观察到纯弥漫性生长模式与高S期分数(大于5%)之间的关系。正如从这种关联所预期的,S期分数高的肿瘤患者的预后比S期分数低的患者更差(生存率14%对57%)。来自12名患者的13个NHL在主要易位簇(MTC)处有可扩增的bcl-1基因重排。bcl-1断点聚集在MTC的一个63 bp区域内,来自每个患者的扩增肿瘤DNA具有独特的N核苷酸连接序列和Ig连接区断点位点。(摘要截短于400字)